Antibiotic utilisation in adult and children patients in Kosovo hospitals.
antibiotic use
point prevalence survey
surveillance
Journal
European journal of hospital pharmacy : science and practice
ISSN: 2047-9956
Titre abrégé: Eur J Hosp Pharm
Pays: England
ID NLM: 101578294
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
28
07
2017
revised:
05
09
2017
accepted:
12
09
2017
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
ppublish
Résumé
There are no reliable data on antibiotic use in Kosovo hospitals. The aim of this survey was to monitor volumes and patterns of antibiotic use in hospitalised patients in order to identify targets for quality improvement. Data on antimicrobial use were collected from seven hospitals in Kosovo during 2013 using the standardised point prevalence survey (PPS) methodology as developed by the ESAC (European Surveillance of Antimicrobial Consumption) and ARPEC (Antibiotic Resistance and Prescribing in European Children). The survey included all inpatients receiving an antimicrobial agent on the day of the PPS. Overall, 1667 patients were included in the study: adults 1345 (81%) and children 322 (19%). Of the hospital inpatients, 579/1345 (43%) adults and 188/322 (58%) children received at least one antibiotic during a hospital stay. The top three antibacterial subgroups (ATC level 3) were β-lactam antibiotics, cephalosporins and aminoglycosides. In all hospital centres, the most commonly prescribed antibiotic was ceftriaxone (39% for adult and 36% for children). Antibiotics were administered mainly parenterally in 74% of adults and 94% of children. Empirical prescribing was higher in adults 498/579 (86%) and children 181/188 (96%), compared with targeted treatment based on susceptibility testing-81 (14%) and 8 (4%), respectively. Antibiotic use in Kosovo's hospitals is very high. Gathered data will be an important tool to identify targets for quality improvement and will support preparation of guidelines and protocols for the prudent use of antibiotics.
Identifiants
pubmed: 31428322
doi: 10.1136/ejhpharm-2017-001363
pii: ejhpharm-2017-001363
pmc: PMC6684012
doi:
Types de publication
Journal Article
Langues
eng
Pagination
146-151Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Infect Control Hosp Epidemiol. 2000 Jun;21(6):394-7
pubmed: 10879571
Emerg Infect Dis. 2002 Mar;8(3):278-82
pubmed: 11927025
Emerg Infect Dis. 2003 Feb;9(2):211-6
pubmed: 12603992
Emerg Infect Dis. 2003 Sep;9(9):1089-95
pubmed: 14519245
Pharmacotherapy. 2005 Feb;25(2):289-98
pubmed: 15767243
Eur J Public Health. 2007 Apr;17(2):226-30
pubmed: 16887834
J Antimicrob Chemother. 2008 Oct;62(4):830-6
pubmed: 18593724
Expert Rev Anti Infect Ther. 2008 Oct;6(5):751-63
pubmed: 18847410
Clin Microbiol Infect. 2009 Apr;15 Suppl 3:12-5
pubmed: 19366364
J Antimicrob Chemother. 2010 Oct;65(10):2247-52
pubmed: 20713405
J Antimicrob Chemother. 2011 Feb;66(2):443-9
pubmed: 21084362
Br J Clin Pharmacol. 2011 Feb;71(2):293-6
pubmed: 21219412
Curr Clin Pharmacol. 2011 Feb;6(1):62-70
pubmed: 21235461
Mayo Clin Proc. 2011 Feb;86(2):156-67
pubmed: 21282489
Intern Med J. 2011 Jun;41(6):441-9
pubmed: 21309997
J Antimicrob Chemother. 2011 Dec;66 Suppl 6:vi25-35
pubmed: 22096063
J Chemother. 2011 Dec;23(6):341-4
pubmed: 22233817
Eur J Clin Pharmacol. 2013 Mar;69(3):599-604
pubmed: 22832725
Euro Surveill. 2012 Nov 15;17(46):null
pubmed: 23171822
Med J Aust. 2013 Mar 18;198(5):241
pubmed: 23496384
Pediatr Infect Dis J. 2013 Jun;32(6):e242-53
pubmed: 23838740
Am J Kidney Dis. 2014 Mar;63(3):422-8
pubmed: 24189475
Lancet Infect Dis. 2013 Dec;13(12):1057-98
pubmed: 24252483
Lancet Infect Dis. 2014 May;14(5):381-7
pubmed: 24657114
Lancet Infect Dis. 2014 Dec;14(12):1220-7
pubmed: 25455989
Infect Control Hosp Epidemiol. 2016 Jan;37(1):70-9
pubmed: 26456803
BMJ Open. 2015 Nov 03;5(11):e008326
pubmed: 26534731
J Antimicrob Chemother. 2016 Apr;71(4):1106-17
pubmed: 26747104
Int J Antimicrob Agents. 1998 May;10(2):161-4
pubmed: 9716293